These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10369118)

  • 1. Multiple regression analysis of interference effects from a hemoglobin-based oxygen carrier solution.
    Kazmierczak SC; Catrou PG; Best AE; Sullivan SW; Briley KP
    Clin Chem Lab Med; 1999 Apr; 37(4):453-64. PubMed ID: 10369118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simplified interpretative format for assessing test interference: studies with hemoglobin-based oxygen carrier solutions.
    Kazmierczak SC; Catrou PG; Boudreau D
    Clin Chem; 1998 Nov; 44(11):2347-52. PubMed ID: 9799763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution.
    Przybelski RJ; Daily EK; Kisicki JC; Mattia-Goldberg C; Bounds MJ; Colburn WA
    Crit Care Med; 1996 Dec; 24(12):1993-2000. PubMed ID: 8968267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hemoglobin- and Perflubron-based oxygen carriers on common clinical laboratory tests.
    Ma Z; Monk TG; Goodnough LT; McClellan A; Gawryl M; Clark T; Moreira P; Keipert PE; Scott MG
    Clin Chem; 1997 Sep; 43(9):1732-7. PubMed ID: 9299968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and mathematical correction of hemolysis interference in selected Hitachi 717 assays.
    Jay DW; Provasek D
    Clin Chem; 1993 Sep; 39(9):1804-10. PubMed ID: 8375051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hitachi Hemolytic Index correlates with HBOC-201 concentrations: impact on suppression of analyte results.
    Moon-Massat PF; Tierney JP; Hock KG; Scott MG
    Clin Biochem; 2008 Apr; 41(6):432-5. PubMed ID: 18178161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction of patient results for Beckman Coulter LX-20 assays affected by interference due to hemoglobin, bilirubin or lipids: a practical approach.
    Vermeer HJ; Steen G; Naus AJ; Goevaerts B; Agricola PT; Schoenmakers CH
    Clin Chem Lab Med; 2007; 45(1):114-9. PubMed ID: 17243928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interference in clinical chemistry assays by the hemoglobin-based oxygen carrier, Hemospan.
    Cameron SJ; Gerhardt G; Engelstad M; Young MA; Norris EJ; Sokoll LJ
    Clin Biochem; 2009 Feb; 42(3):221-4. PubMed ID: 19028481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of hemolysis on routine clinical chemistry testing.
    Lippi G; Salvagno GL; Montagnana M; Brocco G; Guidi GC
    Clin Chem Lab Med; 2006; 44(3):311-6. PubMed ID: 16519604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interference by haemolysis, icterus and lipaemia in assays on the Beckman Synchron CX5 and methods for correction.
    Randall AG; Garcia-Webb P; Beilby JP
    Ann Clin Biochem; 1990 Jul; 27 ( Pt 4)():345-52. PubMed ID: 2403233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemolysis indexes for biochemical tests and immunoassays on Roche analyzers: determination of allowable interference limits according to different calculation methods.
    Monneret D; Mestari F; Atlan G; Corlouer C; Ramani Z; Jaffre J; Dever S; Fressart V; Alkouri R; Lamari F; Devilliers C; Imbert-Bismut F; Bonnefont-Rousselot D
    Scand J Clin Lab Invest; 2015 Apr; 75(2):162-9. PubMed ID: 25608598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the interference of hemoglobin, bilirubin, and lipids on Roche Cobas 6000 assays.
    Ji JZ; Meng QH
    Clin Chim Acta; 2011 Aug; 412(17-18):1550-3. PubMed ID: 21575617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter evaluation of the interference of hemoglobin, bilirubin and lipids on Synchron LX-20 assays.
    Steen G; Vermeer HJ; Naus AJ; Goevaerts B; Agricola PT; Schoenmakers CH
    Clin Chem Lab Med; 2006; 44(4):413-9. PubMed ID: 16599834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A liquid-stable reagent for lactic acid levels. Application to the Hitachi 911 and Beckman CX7.
    Artiss JD; Karcher RE; Cavanagh KT; Collins SL; Peterson VJ; Varma S; Zak B
    Am J Clin Pathol; 2000 Jul; 114(1):139-43. PubMed ID: 10884809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trace element analyses of diaspirin cross-linked hemoglobin solutions.
    Marshall T; Weltzer J; Hai T; Estep T; Farmer M
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):453-6. PubMed ID: 1391463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytical interference of HBOC-201 (Hemopure, a synthetic hemoglobin-based oxygen carrier) on four common clinical chemistry platforms.
    Korte EA; Pozzi N; Wardrip N; Ayyoubi MT; Jortani SA
    Clin Chim Acta; 2018 Jul; 482():33-39. PubMed ID: 29580857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergency Resuscitation of Patients Enrolled in the US Diaspirin Cross-linked Hemoglobin (DCLHb) Clinical Efficacy Trial.
    Sloan EP; Koenigsberg M; Weir WB; Clark JM; O'Connor R; Olinger M; Cydulka R
    Prehosp Disaster Med; 2015 Feb; 30(1):54-61. PubMed ID: 25499006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-specific modifications and toxicity of blood substitutes. The case of diaspirin cross-linked hemoglobin.
    D'Agnillo F; Alayash AI
    Adv Drug Deliv Rev; 2000 Feb; 40(3):199-212. PubMed ID: 10837790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A role for endothelin and nitric oxide in the pressor response to diaspirin cross-linked hemoglobin.
    Schultz SC; Grady B; Cole F; Hamilton I; Burhop K; Malcolm DS
    J Lab Clin Med; 1993 Sep; 122(3):301-8. PubMed ID: 8409706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for using multiple regression analysis with complex interferences.
    Kroll MH; Chesler R
    Eur J Clin Chem Clin Biochem; 1992 Jul; 30(7):415-24. PubMed ID: 1525264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.